Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients
✍ Scribed by Jacoba G. Tibben; Otto C. Boerman; Leon F. A. G. Massuger; Charles P. T. Schijf; Roland A. M. J. Claessens; Frans H. M. Corstens
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- French
- Weight
- 856 KB
- Volume
- 66
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
The bispecific monoclonal antibody (biMAb) OC/TR combines the anti-ovarian-cancer reactivity of the MOvl8 monoclonal antibody (MAb) with the reactivity of an anti-CD3 MAb. Pre-clinical studies have indicated that this biMAb is able to redirect the cytolytic activity of T cells towards tumour cells, resulting in efficient tumour-cell lysis. To assess the clinical potential of systemic biMAb-based cancer therapy we initiated a study in ovarian-cancer patients. Five patients suspected of ovarian cancer received '231-OC/TR F(ab'), i.v. Unexpectedly, the first patient developed side effects (grade Ill-IV toxicity) starting 30 min after infusion (PA) of I mg of OC/TR F(ab')z.